Exempt PVA for drugs with claims less than ₩10 billion
By Lee, Hye-Kyung | translator Alice Kang
21.12.15 06:00:55
가나다라
0
Pharma industry will not accept the 'less than 90% of the arithmetic mean' criteria…requests to retain the current plan in place
Suggests adding ‘low-priced drugs’ to those eligible for price discount rate reduction
The pharmaceutical industry officially delivered its position that it cannot accept any of the measures set for the improvement of the detailed guidelines for the Price-Volume Agreement negotiations that were disclosed by the National Health Insurance Service.
The NHIS had collected industry opinion until the 14th after disclosing the proposed revisions to the KPBMA, KRPIA, and KOBIA at the 10th public-private consultative meeting that was held on the 2nd.
In particular, the KPBMA opposed both the revision of Article 6.1.1 of the guideline that calls for expanding the total claims amount set for a product group from 'less than ₩1.5 billion' to 'less than ₩2 billion,'
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)